Navigation Links
QRxPharma Granted Additional US Patent on MoxDuo®
Date:5/23/2012

SYDNEY and BEDMINSTER, N.J., May 23, 2012 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the United States Patent and Trademark Office (USPTO) issued the Company U.S. Patent No. 8,182,837, which does not expire until 2023.  This patent covers a method of treatment of pain comprising the administration of the oral Dual Opioid® compositions of MoxDuo IR (Immediate Release) for the treatment of acute pain as well as MoxDuo CR (Controlled Release) for the treatment of chronic pain.

"This patent is a key component of our intellectual property (IP) portfolio that provides long term market exclusivity for QRxPharma's MoxDuo opioid products for the treatment of acute and chronic pain," said Dr. John Holaday, Managing Director and Chief Executive Officer.  "This issued patent expands our global IP protection as we look to the commercialisation of our first product, MoxDuo IR, in the third quarter of this year."

The original composition of matter patent granted by the USPTO (U.S. Patent No. 6,310,072) covers the combination of morphine and oxycodone and provides coverage until 2016.  The newly issued patent is directed to a method of treatment of pain using MoxDuo's composition as defined ratio of morphine/oxycodone (3/2), and will not expire until 2023.  Further patents granted in 2011 (U.S. Patents Nos. 7,923,453 and 8,012,990) extend MoxDuo IR IP protection to 2029 and cover a proprietary dosing algorithm for converting patients from intravenous opioid administration to MoxDuo IR, thereby more effectively and safely managing acute pain following surgery.

In April, QRxPharma announced the successful completion of two Phase 1 studies in healthy volunteers for MoxDuo CR, a controlled-release Dual-Opioid utilising a 3:2 ratio of morphine and oxycodone.  The proprietary MoxDuo CR formulation, encompassing both sustained delivery technology as well as abuse deterrent and
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NEW YORK und KISSING, Deutschland, ... ein Hersteller und Distributor eines computerunterstützten („robotischen") ... Nachum (Homi) Shamir , ein weltweit ... seines Leitungs- und Kontrollgremiums zum Unternehmen stößt. ... Shamir ist ein hochangesehener ...
(Date:7/31/2014)... July 31, 2014 Orexigen® Therapeutics, Inc. (Nasdaq: ... the second quarter 2014, on Thursday, August 7, 2014 ... a live webcast and conference call at 8:00 a.m. ... management will host the call and webcast to discuss ... may be accessed by calling (800) 708-4540 (domestic) or ...
(Date:7/31/2014)... 2014 Nutrastar International Inc. (OTCQB: NUIN; "Nutrastar" ... premium branded consumer products, including commercially cultivated Cordyceps Militaris ... announced the signing of its first distributor for its ... Hubei Province located ... . The contract with the ...
Breaking Medicine Technology:invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 2invendo medical holt Nachum (Homi) Shamir in den Board of Directors des Unternehmens 3Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
... and PARIS, Feb. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Sanofi-aventis (EURONEXT: ... it has completed the previously announced acquisition of BMP ... stockholders held today, BMP Sunstone stockholders approved the adoption ... Star 2010, Inc., a wholly owned subsidiary of sanofi-aventis, ...
... Conn., Feb. 24, 2011 Mira Dx announced today that ... acceptance of a pivotal breast cancer study in the January ... BRCA1 coding sequence mutations are associated with breast ... less than 5% of breast cancer risk. The research identified ...
Cached Medicine Technology:Sanofi-Aventis Announces Approval and Closing of BMP Sunstone Acquisition Creating a Strong Consumer Health Care Platform in China 2Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... July 31, 2014 The VitalSleep anti snoring device ... forward to help open a snorers airway to quiet snoring. ... helped her relationship with her husband by allowing them to ... years old. My snoring began about 15 years ago and I ... children could not sleep and had to head downstairs for any ...
(Date:7/31/2014)... 31, 2014 The controversy surrounding ... LLP notes that Johnson & Johnson’s Ethicon, Inc. ... remove its power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) from ... the company said it decided to do so ... devices remain uncertain.* , “In light of mounting ...
(Date:7/31/2014)... July 31, 2014 Infection prevention and ... and maintenance of products in the pharma, medical device, ... by using various products and equipment types; the two ... various materials and products. , The world market ... forecast to post a CAGR of about 7.5% through ...
(Date:7/31/2014)... HealthDay Reporter THURSDAY, July 31, 2014 (HealthDay ... has shown an increased risk of spreading undetected cancers in ... market. In a letter that was to be sent ... that its laparoscopic power morcellators be returned to the company, ... of new morcellators had been suspended in April after the ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 2Health News:J&J Pulls Hysterectomy Tool Tied to Cancer Risk From Market 3
... associated with enhanced communications between families and caregivers, ... for children dying from cancer, according to study ... Hospital Boston. , Published in the April 1 ... study,s findings also suggest that the parents were ...
... that Planned Parenthood affiliates in Florida,have been falsifying ... show,that what happened in California is not an ... Life League,renewed its call for a national investigation ... Florida allege falsified annual,reports., "It,s outrageous that ...
... Consultancy to Address Circle of Patient Care, ... Mike Marolt, president of St.,Paul-based eq-life(R), announced ... to provide pharmacy operations consulting to,hospital organizations ... a,multi-year agreement with Omaha-based Alegent Health to ...
... and TAMPA, Fla., March 28 ... LLC (myMatrixx) are pleased to,announce an ... bill review program and myMatrixx,s pharmacy ... first fully-integrated and automated,program between a ...
... Darwin,Professional Underwriters, Inc. (Darwin) (NYSE: DR ... Romano, who served as its senior vice ... Romano has become,associated with a competing professional ... http://www.newscom.com/cgi-bin/prnh/20060829/NETU014LOGO ), The company ...
... March 28 Conseco, Inc. (NYSE:,CNO) announced today that ... for,the year ended December 31, 2007 with the Securities ... common stock for 2007 was $194.0,million, compared to the ... 2008 preliminary results. The reported net loss applicable to,common ...
Cached Medicine News:Health News:Study finds improvement in the care of children with cancer at the end of life 2Health News:Study finds improvement in the care of children with cancer at the end of life 3Health News:American Life League: Planned Parenthood Scandals 'Widespread' 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 2Health News:eq-life(R) and Fairview Pharmacy Services Announce Multi-Year Consulting Contract with Alegent Health 3Health News:Rising Medical Solutions Partners With myMatrixx to Deliver Integrated Pharmacy Management Solutions 2Health News:Darwin Announces Departure of Senior Vice President 2Health News:Conseco Files 10-K and Sets Earnings Release Date 2
HbA1c / HbCalibrator...
Control Plasma for Assays of Low MolecularWeight Heparins (LMWH) using Anti-Xa Method on STA© Analyzers....
... Abnormal Control Plasmas for ... D-dimer and Free Protein ... For use with STA© ... D-DI (#0515) andSTA© LIATEST© ...
CRP Full Range (0.1-160mg/l)...
Medicine Products: